Kevin Koch

Venture Partner at OrbiMed Advisors LLC

Kevin Koch

Kevin Koch

Venture Partner at OrbiMed Advisors LLC

Overview
Career Highlights

Edgewise Therapeutics, Inc.
Array BioPharma Inc.

RelSci Relationships

2222

Number of Boards

1

Birthday

1960

Age

60

Relationships
RelSci Relationships are individuals Kevin Koch likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Silverback Therapeutics, Inc.

Relationship likelihood: Strong

Founding General Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

General Partner & Co-Head of Global Private Equity at OrbiMed Advisors LLC

Relationship likelihood: Strong

Founding Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

General Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Venture Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Founder & General Partner at Boulder Ventures Ltd.

Relationship likelihood: Strong

Distinguished Professor of Chemistry & Biochemistry at The University of Colorado

Relationship likelihood: Strong

General Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

General Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Paths to Kevin Koch
Potential Connections via
Relationship Science
You
Kevin Koch
Venture Partner at OrbiMed Advisors LLC
Education
Ph.D. in Synthetic Organic Chemistry

The University of Rochester is a private, nonsectarian, research university in Rochester, New York, United States. The university grants undergraduate and graduate degrees, including doctoral and professional degrees. The university has six schools and various interdisciplinary programs. The University of Rochester is noted for its Eastman School of Music. The university is also home to the Institute of Optics, founded in 1929, the first educational program in the US devoted exclusively to optics. Rochester's Laboratory for Laser Energetics is home to the second most energetic fusion laser in the world.

Stony Brook University is one of America’s most dynamic public universities, a center of academic excellence and an internationally recognized research institution that is changing the world. After less than 60 years of existence, it’s ranked among the top 100 universities in the nation.

Career History
President, Chief Executive Officer & Director
2017 - Current

Edgewise Therapeutics, Inc. develops novel therapies for skeletal muscle diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Venture Partner
Current

OrbiMed Advisors generally seeks long-term capital appreciation through investments in companies in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm employs a disciplined investment style and achieves diversification within the global healthcare sector, with the goal of creating attractive risk-adjusted returns.

Venture Partner
Current

OrbiMed focuses exclusively on global investments across the entire spectrum of private and publicly-traded life sciences companies. They seek to invest in the most promising investment opportunities regardless of a company's stage of development. The firm invests at all stages of development from private start-ups and university spinouts to the largest global pharmaceutical companies. OrbiMed focuses on companies involved in drug development, drug discovery and medical devices, with particular emphasis on mid-stage private companies. Investments typically range from $5 million to $40 million. OrbiMed is generally a lead investor and takes an active role on their portfolio companies' boards of directors

Boards & Committees
Director
2018 - Current

Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA.

President, Chief Executive Officer & Director
2017 - Current

Edgewise Therapeutics, Inc. develops novel therapies for skeletal muscle diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Director
Current

Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA.

Director
1998 - 2003

Inflammation Research Association, Inc. engages in encouraging scientists, researchers, students, teachers and clinicians with an interest in inflammation biology. The company is headquartered in Newcastle, WA.

Transactions
Details Hidden

Edgewise Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Array BioPharma Inc. raised money in a private placement transaction

Investments
Details Hidden

Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kevin Koch. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kevin Koch's profile does not indicate a business or promotional relationship of any kind between RelSci and Kevin Koch.